L’expérience du sacré à travers les lieux de rituels dans l’architecture

[EN] The social and spatial structures, the code as well as the languages recognized and created by the masters of the past are no longer adequate in our present time. Belonging to these structures today is no longer associated with the community but with the network.[CA] Les estructures socials i espacials, així com els llenguatges reconeguts i creats pels mestres del passat ja no són adequats en la nostra època actual. La pertinença a aquestes estructures hui ja no s’associa a la comunitat sinó a la xarxa.[ES] Las estructuras socioespaciales, los códigos así como los lenguajes reconocidos y creados por los maestros del pasado ya no son adecuados en nuestros días. Pertenecer a dichas estructuras hoy ya no se asocia a la comunidad sino al sistema.[FR] Les structures socio-spatiales, les codes ainsi que les langages reconnus et créés par les maîtres du passé ne sont plus indiqués de nos jours. Aujourd’hui, appartenir à ces structures n’est plus associé à la communauté mais au système.Rugino, S. (2021). L’experiència del Sagrat a través dels llocs rituals en l’arquitectura. ANUARI d’Arquitectura i Societat. 0(1):198-214. https://doi.org/10.4995/anuari.2021.16055OJS19821401AA.VV. Metapolis. Barcelona: Actar, 2004.Baudrillard, Jean. Simulacri e impostura. Bestie, beaubourg, apparenze e altri oggetti. Roma: PGreco, 2008,1981.Bauman, Zigmunt. Intervista sull'identità. Roma-Bari: Laterza, 2003.Binford, Sally, R. New Perspectives in Archaeology. Chicago: Aldine Transaction, 1968.Koolhaas, Rem. Junkspace. Macerata: Quodlibet, 2006.Orwell, George. 1984. Milan: Arnaldo Mondatori Editore, 1983.Zardini, Mirko. Paesaggi Ibridi. Milan: Skira, 1999.Turner, Victor. Dal rito al teatro. Bologna: Il Mulino, 2014

Eksédra 2008

Il volume affronta temi relativi al disegno, al rilievo ed alla progettazione architettonica

Retrospective Case Series of Aripiprazole Augmentation in Pervasive Developmental Disorders

Due to co-morbidities and treatment resistant nature of pervasive developmental disorder (PDD), diverse combinations of regimens have been tried. This retrospective study aimed to explore adjunctive use of aripiprazole in children with PDD. Changes in illness severity were measured by Clinical Global Impression of Severity (CGI-S) and Clinical Global Impression of Improvement (CGI-I) in 14 aripiprazole-treated patients with PDD. Improvement of illness severity was observed after aripiprazole add-on (5.8±0.8 to 4.9±1.0, Z=-2.75, p=0.001). Mean dosage was 7.7 mg/day [standard deviation (SD) 3.3, range 5-15]. A higher mean dosage was observed in group with improvement in symptoms (t=-2.33, df =12, p=0.004). The target symptoms most effectively improved after using aripiprazole were positive psychotic symptoms (mean CGI-I: 2.0±1.4, 3 responders/4 patients, 75% response) followed by aggressive behavior (2.5±1.7, 3/4, 75%), self-injurious behavior (2.0±1.0, 2/3, 67%), stereotypic behavior (2.7±1.2, 2/3, 67%), tic (2.8±1.0, 2/4, 50%), irritability (3.5±2.1, 1/2, 50%), obsessive behavior (2.5±2.1, 1/3, 33%), hyperactivity (3.4±1.6, 3/7, 43%) and mood fluctuation (3, 0/1, no response). Five patients (35%) discontinued aripiprazole due to treatment-emergent adverse effects (akathisia, insomnia, withdrawal). The results of this study suggest that aripiprazole augmentation may be used safely in maladaptive behaviors of some populations of PDD. However, future studies are required to confirm these preliminary findings

Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder?

Background: To evaluate health-related quality of life (HRQL) and medication satisfaction after switching from a stable dose of oral extended-release methylphenidate (ER-MPH) to methylphenidate transdermal system (MTS) via a dose-transition schedule in children with attention-deficit/hyperactivity disorder (ADHD). Methods: In a 4-week, multisite, open-label study, 171 children (164 in the intent-to-treat [ITT] population) aged 6-12 years diagnosed with ADHD abruptly switched from a stable dose of oral ER-MPH to MTS nominal dosages of 10, 15, 20, and 30 mg using a predefined dose-transition schedule. Subjects remained on the scheduled dose for the first week, after which the dose was then titrated to an optimal effect. The ADHD Impact Module-Children (AIM-C), a disease-specific validated HRQL survey instrument measuring child and family impact, was used to assess the impact of ADHD symptoms on the lives of children and their families at baseline and study endpoint. Satisfaction with MTS use was assessed via a Medication Satisfaction Survey (MSS) at study endpoint. Both the AIM-C and MSS were completed by a caregiver (parent/legally authorized representative). Tolerability was monitored by spontaneous adverse event (AE) reporting. Results: AIM-C child and family HRQL mean scores were above the median possible score at baseline and were further improved at endpoint across all MTS doses. Similar improvements were noted for behavior, missed doses, worry, and economic impact AIM-C item scores. Overall, 93.8% of caregivers indicated a high level of satisfaction with their child's use of the study medication. The majority of treatment-emergent AEs (> 98%) were mild to moderate in intensity, and the most commonly reported AEs included headache, decreased appetite, insomnia, and abdominal pain. Seven subjects discontinued the study due to intolerable AEs (n = 3) and application site reactions (n = 4). Conclusion: This study demonstrates that MTS, when carefully titrated to optimal dose, may further improve child and family HRQL, as well as behavioral, medication worry, and economic impact item scores, as measured by the AIM-C in subjects switching to MTS from a stable dose of routinely prescribed oral ER-MPH after a short treatment period. Furthermore, following the abrupt conversion from oral ER-MPH to MTS, the majority of caregivers reported being highly satisfied with MTS as a treatment option for their children with ADHD. Trial Registration: NCT0015198

Liquid box

Questo volume nasce come volontà di relazionare le tante discipline che hanno anticipato la condizione di “liquidità” dello spazio dell’architettura. Dobbiamo riconoscere di essere sulla linea di partenza di una “logica liquida” che è fortemente avallata dalle tecnologie digitali che formano e in-formano nuovi modi di abitare. Questi, flessibili e aperti alle nuove condizioni determinate da fattori esterni alla disciplina dell’architettura, non sono matematici e neanche prevedibili, sono semplicemente delle nuove organizzazioni. Posseggono la capacità dei liquidi, cioè quella di non avere una forma determinata, ma adattabile al contenitore o al contenuto, e appartengono allo spazio non euclideo. Riconosciamo di vivere una nuova realtà, dove le tecnologie dell’informazione incoraggiano una forma dell’abitare come rete, connessa ad altre reti e in continua trasformazione, e in quella dove l’architettura e le città devono essere pensate in maniera totalmente nuova e innovativa. In questa nuova realtà, l’architettura si esprime attraverso nuove parole, termini, significati che esprimono completamente l’attuale trasformazione culturale